We analyzed the incidence, clinicopathological features, risk factors and prognosis of patients with EBV-associated post-transplant lymphoproliferative disorder (EBV-PTLD) in 288 adults undergoing umbilical cord blood transplantation (UCBT) at a single institution. Twelve patients developed proven EBV-PTLD at a median time of 73 days (range, 36-812). Three-year cumulative incidence (CI) of EBV-PTLD was 4.3% (95% CI: 1.9-6.7). All patients presented with extranodal involvement. Most frequently affected sites were the liver, spleen, central nervous system (CNS), Waldeyer's ring and BM in 7, 6, 4, 3 and 3 patients, respectively. One patient had polymorphic and 11 had monomorphic EBV-PTLD (7 diffuse large B-cell lymphomas not otherwise specified, 4 plasmablastic lymphomas). We confirmed donor origin and EBV infection in all histological samples. EBV-PTLD was the cause of death in 11 patients at a median time of 23 days (range, 1-84). The 3-year CI of EBV-PTLD was 12.9% (95% CI: 3.2-22.5) and 2.6% (95% CI: 0.5-4.7) for patients receiving reduced-intensity conditioning (RIC) and myeloablative conditioning, respectively (Po0.0001). In conclusion, adults with EBV-PTLD after UCBT showed frequent visceral and CNS involvement. The prognosis was poor despite routine viral monitoring and early intervention. An increased risk of EBV-PTLD was noted among recipients of RIC regimens.
INTRODUCTION
EBV-associated post-transplant lymphoproliferative disorder (EBV-PTLD) is a feared complication after allo-SCT that is associated with significant morbidity and mortality. Risk factors for EBV-PTLD are related to the imbalance between EBV T-cell response and proliferation of latent B-lymphocytes that is thought to be the underlying mechanism of the disease. 1 Among recipients of an umbilical cord blood transplant (UCBT), a markedly increased risk of EBV-PTLD has been reported previously after reduced-intensity conditioning (RIC) regimens that included antithymocyte globulin (ATG). 2, 3 These studies focused on describing risk factors for this complication and included both children and adults. However, clinical and histopathological features at presentation, outcome as well as other risk factors for EBV-PTLD after UCBT in adults are not well defined.
The aim of the present study was to analyze the incidence of EBV-PTLD and characterize the presenting features, histopathological findings, response to therapy and outcome of individuals who developed this complication. We also analyzed risk factors for the development of EBV-PTLD in adults with hematologic diseases undergoing UCBT at a single institution.
PATIENTS AND METHODS

Eligibility criteria
All adult patients undergoing UCBT from unrelated donors at Hospital Universitario La Fe between May 1997 and December 2012 were included in the study. The institutional review board approved the protocol and written informed consent was obtained from all patients according to the Declaration of Helsinki. The treatment plans including graft selection, conditioning regimen, immune suppression and supportive care have been reported in detail previously, [4] [5] [6] and are summarized below.
Conditioning regimen
The choice of conditioning regimen was made on an individual basis according to age, baseline diagnosis and previous transplantation. Two hundred and forty-one patients received two subsequent myeloablative conditioning (MAC) regimens based on the combination of thiotepa, BU, CY or fludarabine, and ATG. Until March 2005, 71 patients received thiotepa (10 mg/kg), BU (12 mg/kg peritoneally in 44 patients or 9.6 mg/kg intravenously in 27 patients), CY (120 mg/kg) and ATG (Lymphoglobuline (Merieux, Lyon, France); 60 mg/kg in the first 32 patients or Thymoglobulin (Genzyme Transplant, Cambridge, MA, USA); 8 mg/kg in the remaining 39 patients). From March 2005, the remaining 170 patients received thiotepa (10 mg/kg), intravenous BU as a single dose (9.6 mg/kg), fludarabine (150 mg/m 2 ) and ATG (Thymoglobulin 8 mg/kg in the first 50 patients and 6 mg/kg in the remaining 120 patients).
Forty-seven patients received a RIC regimen. Thirteen patients with aplastic anemia received CY (50 mg/kg), fludarabine (160 mg/m 2 ) and ATG (Thymoglobulin 8 mg/kg). Of the remaining 34 patients, nine received thiotepa (5 mg/kg), fludarabine (150 mg/m 2 ), CY (50 mg/kg) and ATG (Thymoglobulin 6 mg/kg) and 25 patients received thiotepa (5 mg/kg), fludarabine (150 mg/m 2 ), intravenous BU as a single dose (6.4 mg/kg) and ATG (Thymoglobulin 8 mg/kg).
GVHD prophylaxis and treatment
All patients received CYA 1.5 mg/kg/12 h intravenously, followed by 3-5 mg/kg/12 h orally when oral intake was possible, with slow tapering starting between day þ 90 and þ 180 and discontinuation on day þ 180 or before if feasible. CYA was combined with long-course prednisone in the first 142 patients (0.5 mg/kg/day on days þ 7 to þ 14, 1 mg/kg/day on days þ 14 to þ 28, with slow tapering until discontinuation on day þ 180), mycophenolate mofetil (15 mg/kg/12 h until day þ 28) in the following 85 patients, or a short course of prednisone in the last 61 patients (1 mg/kg/ day on days þ 14 to þ 28). Patients developing acute GVHD received high-dose methylprednisolone as initial therapy (20 mg/kg/day; halving the dose every 3 days until reaching 1 mg/kg/day, and then gradually tapered), followed by ATG in refractory cases. Chronic GVHD was treated with prednisone 1 mg/kg/day.
Definitions, EBV monitoring and management and chimerism evaluation EBV viremia, proven EBV-PTLD and pre-emptive therapy were defined according to the European Conference on Infections in Leukemia guidelines. 7 Cases of proven EBV-PTLD were further classified according to the WHO criteria. 8 EBV monitoring was performed by routine screening of plasma samples for every patient since 2005. DNA was extracted from plasma (250 ml) samples using EasyMag (BioMé rieux, France). Quantitative real-time PCR was carried out with 5 ml of DNA with Simplexa EBV kit (Focus Diagnostics, USA) following the manufacturer's instructions and using the 3M Integrated Cycler (USA).The cutoff value for test positivity was 900 copies of EBV DNA per milliliter of plasma. Testing was performed weekly from day þ 7 until day þ 100, every 2 weeks until day þ 180, and monthly thereafter for the first year. Patients with EBV viremia detected on at least two consecutive samples were considered to have an EBV reactivation and were evaluated with whole-body computed tomography or other tests as clinically indicated in order to detect significant lymphoid proliferation. If a diagnosis of EBV-PTLD was made the therapeutic options for patients consisted in the administration of rituximab as monotherapy, the reduction of immunosuppression and chemoimmunotherapy when feasible.
Chimerism analysis was performed by PCR amplification of STR markers using DNA from tumor samples as described previously. 9 
Statistical analysis
Characteristics of patients receiving MAC or RIC were compared using the w 2 test for categorical variables and Wilcoxon's rank-sum test for continuous variables. The probabilities of EBV reactivation and EBV-PTLD were estimated by the cumulative incidence (CI) method (marginal probability) and for comparisons the Gray test was used. 10, 11 For CI analyses, relapse and death without EBV reactivation were considered as competing causes of failure. The Fine and Gray method for competing events was used for multivariable analysis using variables with a P-value o0.10 for each end point. 11 Variables included in the model were: conditioning regimen (MAC vs RIC), diagnosis, age, gender, recipient CMV and EBV serostatus, disease stage at transplantation, previous transplant, HLA compatibility considering low-resolution typing for class I and highresolution typing for class II Ags, GVHD prophylaxis, acute and chronic GVHD and total nucleated cell and CD34 þ cell count before freezing and infusion. Statistical analyses were conducted using R version 2.12.2 (The CRAN project) with packages, Design 2.3-0, prodlim v.1.2.1 and cmprsk v.2.2-2.
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RESULTS
Patient, transplant and graft characteristics
Two hundred and eighty-eight consecutive adult patients underwent single-unit unrelated donor UCBT and were included in the analysis. Patient and transplant characteristics according to the conditioning regimen are summarized in Table 1 . Briefly, 241 patients (84%) received an MAC, whereas the remaining 47 (16%) received an RIC. Median age was 34 years and 46 years in MAC and RIC groups, respectively (Po0.0001). Table 2 summarizes the characteristics of the cord blood units. Donor-recipient HLA disparity was similar between MAC and RIC groups, with 72% and 71% receiving a 4/6 matched graft, respectively. Median number of total nucleated cells and CD34 þ cells infused was higher in patients who received an RIC regimen.
Transplant outcomes
Overall CI incidence of myeloid engraftment at 60 days was 92% with a median time to neutrophil recovery of 20 days Abbreviation: TNC ¼ total nucleated cell.
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(range, 9-57). CI of acute GVHD grade II-IV and III-V at 100 days, and chronic GVHD at 2 years was 38%, 23% and 55%, respectively. Overall survival of the entire cohort at 5 years was 32% after a median follow-up of 71 months.
EBV reactivation
Fourteen patients developed an EBV reactivation at a median time of 150 days (range, 36-812) after transplantation. Four of them had active Hodgkin's disease (three cases of nodular sclerosis and one mixed cellularity) at the time of UCBT. None of them showed evidence of EBV infection detected by EBV-encoded RNA or latent membrane protein 1 in histological samples at the time of initial diagnosis.
Overall the CI of EBV reactivation at 3 years was 5.0% (95% CI: 2.4-7.5). Six patients received an MAC regimen and eight received an RIC regimen before the UCBT. The median time to development of an EBV reactivation was 164 days (range, 56-812) and 63 days (range, 36-119) for MAC and RIC groups, respectively. Two patients with isolated EBV viremia were successfully treated with pre-emptive rituximab therapy, attaining PCR negativity after two and four doses. The remaining 12 patients had proven EBV-PTLD. Table 3 . Twelve patients developed an EBV-PTLD at a median time of 73 days (range, 36-812) after UCBT. The CI of EBV-PTLD at 3 years was 4.3% (95% CI: 1.9-6.7). Median time elapsed from first detection of EBV viremia to full-blown PTLD was 4 days (range, 0-70). Only two patients had sufficient time after first PCR positivity (43 and 70 days) to receive pre-emptive rituximab monotherapy. Both of them failed pre-emptive therapy and further progressed to PTLD.
EBV-PTLD
All patients presented with extranodal involvement. Most frequently affected sites were: liver, spleen, central nervous system (CNS), Waldeyer's ring and BM in seven, six, four, three and three patients, respectively. Of the four patients with detection of monoclonal lymphoid infiltration in cerebrospinal fluid (CSF) analysis, only two had detectable lesions on magnetic resonance imaging.
Biological features. All patients had biopsy proven PTLD. Details on biological characteristics of tumor samples are shown in Table 4 . According to the WHO classification, one patient had polymorphic EBV-PTLD, whereas the remaining 11 patients had diffuse large B-cell lymphoma (DLBCL) monomorphic EBV-PTLD. Of these, seven were DLBCL not otherwise specified (NOS) with activated B-cell-like phenotype and four were plasmablastic lymphomas. CD20 expression was absent in patients with plasmablastic lymphomas and in one patient with DLBCL NOS. All cases with available information on donor-recipient chimerism demonstrated the donor origin of the lymphoid proliferation. EBV was detected by EBV-encoded RNA or latent membrane protein 1 in all histological samples for which information was available. All cases of monomorphic EBV-PTLD were monoclonal, whereas the single patient with polymorphic EBV-PTLD had a biclonal rearrangement of the IGH gene.
Treatment and outcome
Only one patient with isolated infiltration of the Waldeyer's ring remains alive at last follow-up after receiving rituximab monotherapy. The remaining 11 patients died at a median of 23 days (range, 1-84) after diagnosis. EBV-PTLD was the primary cause of death in 10 patients. Two patients did not receive specific therapy because diagnosis was made perimortem. The remaining patients received rituximab monotherapy and those who progressed and were considered fit were treated with anthracycline-based chemoimmunotherapy. Risk factors for EBV reactivation and PTLD EBV reactivation. In the multivariable analysis, baseline diagnosis of Hodgkin's disease (relative risk, 11.6; 95% CI: 3.4-40.0; Po0.0001) and RIC UCBT (relative risk, 6.0; 95% CI: 2.0-17.6; P ¼ 0.001) were the only independent factors associated with an increased risk of EBV reactivation. The 3-year CI of EBV reactivation was 17.0% (95%: CI 6.4-28.0) and 2.6% (95% CI: 0.5-4.7) for patients receiving RIC and MAC, respectively (Po0.0001). The 3-year CI of EBV reactivation was 44% (95% CI: 12-77) and 3.7% (95% CI: 1.4-6.0) for patients with Hodgkin's disease and other diagnosis, respectively (Po0.0001).
EBV-PTLD. RIC UCBT (relative risk, 5.5; 95% CI: 1.8-17.1; P ¼ 0.003) was the only independent factor associated with an increased risk of EBV-PTLD. The 3-year CI was 12.9% (95% CI: 3.2-22.5) and 2.6% (95% CI: 0.5-4.7) for patients receiving RIC and MAC, respectively (P ¼ 0.001) (Figure 1 ).
DISCUSSION
This study shows that adults with EBV-PTLD after UCBT had a characteristic presentation with extranodal involvement and frequent CNS and liver infiltration, high frequency of monomorphic PTLD, an aggressive clinical course with a short interval between the detection of EBV reactivation and disease progression, poor response to therapy and an ominous prognosis. We also confirmed a relatively low incidence of EBV-PTLD after ATG containing MAC that increased significantly after the administration of RIC regimens. This single-center study included a large series of adults that received a relatively homogeneous chemotherapy-based conditioning regimen. All patients received ATG as part of the conditioning regimen at a dose ranging from 6 to 8 mg/kg. As expected, patients undergoing a RIC transplant were older and more frequently had aplastic anemia as well as lymphoma. Owing to the retrospective nature of the study, and the fact that EBV-PTLD can be easily misdiagnosed as many other disorders have a similar presentation, we cannot rule out the possibility that some cases could have been overlooked and not included in the present series. However, viral load was closely monitored and specific diagnostic tests were performed rapidly after minimal suspicion of the development of EBV-PTLD. The fact that all cases had a proven diagnosis of EBV-PTLD that was confirmed with histopathology and immunophenotype adds strength to our findings.
This study provides novel information on the clinical and histological characteristics at presentation of EBV-PTLD after UCBT. Extranodal involvement was common and the most frequently affected organs were the liver and spleen. Information on sites of involvement at presentation of PTLD after SCT is scarce and is not well defined, especially in the UCBT setting. Previous series have reported a high frequency of extranodal lymphoma with common hepatic involvement. 13, 14 Another important observation was that one-third of patients with EBV-PTLD in the present series had evidence of CNS involvement. Although CNS involvement with PTLD after solid organ transplantation may affect up to 25% of patients, 15, 16 there is little data in the SCT setting. Some series have reported a low incidence of CNS disease. 13, 14 If our findings are confirmed, it could have implications for the management of these patients. First, CSF analysis should be considered as a routine procedure in the staging evaluation, and secondly, treatment options that cross the blood-brain barrier should be considered for these patients. 17 Regarding histological subtypes, the high frequency of monomorphic EBV-PTLD in this study is worth noting. In a large study, Landgren and co-workers report a high frequency of polymorphic PTLD among 127 patients with PTLD after allo-SCT. 18 Differences in patient characteristics and stem cell source could explain the discrepant findings. Four patients had CD20-negative plasmablastic lymphoma, a malignancy that is commonly seen in T-cell immunosuppressed individuals infected with HIV, 8 and that has been marginally described in recipients of stem cell transplants. 19, 20 In this regard, the early period after UCBT is characterized by deep immune suppression with low levels of CD4 þ T cells that could favor the development of this complication. 19 One strength of the present study is the fact that clonality was evaluated in all cases. As expected, we found evidence of monoclonality in cases of monomorphic EBV-PTLD, whereas in the only patient with polymorphic disease two different IGH clonal rearrangements were seen. This supports the hypothesis of a clonal selection in the natural history of a disease that comprises a spectrum of tumors starting with early EBV-driven polyclonal proliferations and evolving to monomorphic and monoclonal disorders. 8 We also were able to establish the donor origin of the malignancy as assessed by chimerism assays. Our findings are consistent with those reported by Ballen and co-workers 21 in an earlier publication. This observation in the UCBT setting where the graft has never been exposed to EBV infection supports the concept that EBV-PTLD is a malignancy derived from naive B-lymphocytes from the donor that become infected with EBV present in the recipient in the absence of EBV-specific memory T cells.
The prognosis of patients was poor. As a matter of fact, EBV-PTLD was the cause of death in most patients and in some of them the diagnosis was made perimortem. Despite the fact that chemoimmunotherapy with an anthracycline-based regimen is an established therapeutic option for PTLD, 7,22,23 most patients could not be treated owing to their poor performance status at the time of diagnosis. Among those who were treated, responses were disappointing and progression of the lymphoproliferative disorder was the rule. Therefore, efforts to reduce the incidence of this complication are highly desirable, especially after RIC transplants and among patients with a diagnosis of Hodgkin's disease. In this regard, T-cell depletion should be used in carefully selected individuals while maintaining a low index of suspicion for EBV-PTLD. 24 Also, the use of prophylactic rituximab in the conditioning regimen may reduce the frequency of EBV-RC in high-risk patients; however, the efficacy of this intervention would have to be determined. A common strategy in transplant units relies on EBV monitoring for high-risk patients to identify EBV reactivation early and institute pre-emptive therapy before the development of fullblown PTLD. 22, 23 However, despite close viral monitoring and early treatment, in our cohort most patients did not benefit from this strategy because the interval between the first identification of EBV viremia and the detection of overt lymphoma was too short. As for possible interventions for established disease, infusion of EBV-specific cytotoxic T-lymphocytes could also be effective after UCBT. 25, 26 Unfortunately, the widespread application of this therapy is limited as it is only available in a reduced group of highly specialized centers.
Finally, we found a CI of EBV-PTLD of 4.3%, similar to that reported previously, regardless of the source of stem cells used for transplantation. [1] [2] [3] We also were able to confirm an increased incidence of this complication among patients that received an RIC regimen before transplantation as described elsewhere.
2,3,13 A novel finding was the increased risk of EBV reactivation that was seen among patients with a baseline diagnosis of Hodgkin's disease. This is an intriguing observation that was raised in a previous report showing a high incidence of EBV-PTLD after allo-SCT in a series of patients with this disease. 27 The association between EBV and Hodgkin's disease pathogenesis is well recognized 28 and EBV DNA can be detected in the plasma of patients with active disease. 29 However, in the present study, despite the fact that patients with Hodgkin's disease were transplanted with high tumor burden, none of them showed evidence of EBV infection in histological samples at the time of initial diagnosis and were all EBV PCR negative at the time of transplantation.
In conclusion, this study further describes the specific clinicopathological features of adults with EBV-PTLD after ATG-containing UCBT. Most patients presented with extranodal disease and frequent visceral and CNS involvement. A high frequency of monomorphic EBV-PTLD, including cases of plasmablastic lymphoma, were found among this group of patients. The prognosis was poor despite routine EBV monitoring and early intervention. An increased risk of EBV reactivation and PTLD was noted among recipients of RIC regimens.
